These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Hashimoto M; Rockenstein E; Crews L; Masliah E Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050 [TBL] [Abstract][Full Text] [Related]
4. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. Coskuner-Weber O; Uversky VN Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151 [TBL] [Abstract][Full Text] [Related]
5. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472 [TBL] [Abstract][Full Text] [Related]
6. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases. Atsmon-Raz Y; Miller Y ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553 [TBL] [Abstract][Full Text] [Related]
7. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579 [TBL] [Abstract][Full Text] [Related]
8. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology. de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516 [TBL] [Abstract][Full Text] [Related]
9. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944 [TBL] [Abstract][Full Text] [Related]
10. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. Majd S; Power JH; Grantham HJ BMC Neurosci; 2015 Oct; 16():69. PubMed ID: 26499115 [TBL] [Abstract][Full Text] [Related]
11. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Williams SM; Schulz P; Sierks MR Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448 [TBL] [Abstract][Full Text] [Related]
12. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892 [TBL] [Abstract][Full Text] [Related]
13. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease. Vella LJ; Hill AF; Cheng L Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304 [TBL] [Abstract][Full Text] [Related]
14. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases. Choi ML; Gandhi S FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502 [TBL] [Abstract][Full Text] [Related]
15. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Forloni G; Artuso V; La Vitola P; Balducci C Mov Disord; 2016 Jun; 31(6):771-81. PubMed ID: 27030592 [TBL] [Abstract][Full Text] [Related]
16. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Gallardo G; Schlüter OM; Südhof TC Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066 [TBL] [Abstract][Full Text] [Related]
17. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases. Wojtunik-Kulesza K; Oniszczuk A; Waksmundzka-Hajnos M Biomed Pharmacother; 2019 Mar; 111():1277-1289. PubMed ID: 30841441 [TBL] [Abstract][Full Text] [Related]
18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. Li J; Liu D; Sun L; Lu Y; Zhang Z J Neurol Sci; 2012 Jun; 317(1-2):1-5. PubMed ID: 22410257 [TBL] [Abstract][Full Text] [Related]
20. Commentary to "Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease". Mandal PK; Pettegrew JW Neurochem Res; 2008 Jun; 33(6):1168. PubMed ID: 18049892 [No Abstract] [Full Text] [Related] [Next] [New Search]